{"entity":{"id":"nct05827016","kind":"trial","name":"A Study to Compare Iberdomide Maintenance Versus Lenalidomide Maintenance Therapy Following Autologous Stem Cell Transplant in Participants With Newly","aka":["EXCALIBER-Maintenance"],"tldr":"A phase 3 trial of Iberdomide, Lenalidomide in multiple myeloma, run by Bristol-Myers Squibb, active and no longer recruiting.","summary":"A Study to Compare Iberdomide Maintenance Versus Lenalidomide Maintenance Therapy Following Autologous Stem Cell Transplant in Participants With Newly Diagnosed Multiple Myeloma is a phase 3 interventional study registered as NCT05827016 by Bristol-Myers Squibb, with 1230 participants enrolled, started 2023-06-22 and due to reach its primary completion in 2029-03-15. Interventions recorded: Iberdomide, Lenalidomide. Conditions listed: Multiple Myeloma. No results are recorded here; the registry entry is the source.","status":"active","asOf":"2026-09-16","links":[{"label":"ClinicalTrials.gov NCT05827016","url":"https://clinicaltrials.gov/study/NCT05827016"}],"tags":["ctgov-ingest"],"related":[],"cancers":["multiple-myeloma","myeloma-transplant-eligible"],"sections":[],"technologies":["celmods","protac-degrader"],"targets":[],"drugs":["iberdomide","lenalidomide"],"companies":["bms"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"nct":"NCT05827016","phase":"3","setting":"A Phase 3, Two-stage, Randomized, Multi-center, Controlled, Open-label Study Comparing Iberdomide Maintenance to Lenalidomide Maintenance Therapy After Autologous Stem Cell Transplantation (ASCT) in Participants With Newly Diagnosed Multiple Myeloma (NDMM) (EXCALIBER-Maintenance)","sponsor":"Bristol-Myers Squibb","participation":[{"nct":"NCT05827016","source":"https://clinicaltrials.gov/study/NCT05827016","fetchedAt":"2026-10-07T16:53:56.649Z","studySha256":"4635ae454b32bb45df3929d1f8704a3395aafd35711da3e51afdf274a22f5e0d","overallStatus":"ACTIVE_NOT_RECRUITING","lastUpdatePosted":"2026-09-17","leadSponsor":"Bristol-Myers Squibb","collaboratorCount":0,"minimumAge":"18 Years","sex":"ALL","healthyVolunteers":false,"hasEligibility":true,"enrolment":1230,"enrolmentType":"ACTUAL","siteCount":269,"recruitingSiteCount":0,"countries":["Argentina","Australia","Austria","Belgium","Brazil","Canada","Chile","China","Colombia","Czechia","Denmark","Finland","France","Germany","Greece","Hong Kong","Hungary","India","Israel","Italy","Japan","Mexico","Netherlands","Poland","Portugal","Romania","Singapore","South Korea","Spain","Sweden","Taiwan","Turkey (Türkiye)","United Kingdom","United States"]}],"started":"2023-06-22","startedType":"actual","enrolled":1230,"enrolledBasis":"registry","outcomes":[]},"route":"/trials/nct05827016/","neighbours":{"cancer":[{"id":"multiple-myeloma","kind":"cancer","name":"Multiple myeloma","route":"/cancers/multiple-myeloma/"},{"id":"myeloma-transplant-eligible","kind":"cancer","name":"Newly diagnosed multiple myeloma, transplant-eligible","route":"/cancers/myeloma-transplant-eligible/"}],"technology":[{"id":"celmods","kind":"technology","name":"Cereblon E3 ligase modulators (CELMoDs)","route":"/technologies/celmods/"},{"id":"protac-degrader","kind":"technology","name":"PROTACs & molecular glues (targeted protein degradation)","route":"/technologies/protac-degrader/"}],"drug":[{"id":"iberdomide","kind":"drug","name":"Iberdomide","route":"/drugs/iberdomide/"},{"id":"lenalidomide","kind":"drug","name":"Lenalidomide","route":"/drugs/lenalidomide/"}],"company":[{"id":"bms","kind":"company","name":"Bristol Myers Squibb","route":"/companies/bms/"}]}}